Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $335000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 7.03% year-over-year to $335000.0, compared with a TTM value of $1.3 million through Dec 2025, up 7.01%, and an annual FY2025 reading of $1.3 million, up 7.01% over the prior year.
  • Depreciation & Amortization (CF) was $335000.0 for Q4 2025 at Xeris Biopharma Holdings, down from $338000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $391000.0 in Q3 2023 and bottomed at $281000.0 in Q2 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $337750.0, with a median of $336000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 27.2% in 2024, then rose 15.66% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $349000.0 in 2021, then increased by 4.87% to $366000.0 in 2022, then fell by 5.46% to $346000.0 in 2023, then decreased by 9.54% to $313000.0 in 2024, then increased by 7.03% to $335000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for XERS at $335000.0 in Q4 2025, $338000.0 in Q3 2025, and $325000.0 in Q2 2025.